IKT News and Press, Inhibikase Therapeutics Inc. From 06/22/23

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study PR Newswire - 600 mg dose of IkT-001Pro selected as the bioequivalent dose relative to standard of care 400 mg imatinib...

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease PR Newswire - Company to highlight the '201' trial at multiple regional seminars for physicians - - Up to 61% of clinical s...

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII PR Newswire BOSTON and ATLANTA , May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing...

--News Direct-- Inhibikase Therapeutics ( IKT ) is a small capitalization company working in both neurology and oncology. Their principal focus is a small molecule inhibitor of c-Abl for the treatment of a number of neurodegenerative disorders with an initial focus on Parkinson’...

2023-05-16 09:38:07 ET Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Conference Call May 16, 2023 08:00 AM ET Company Participants Alex Lobo - Stern IR Milton Werner - President & CEO Joseph Frattaroli - CFO Conference Call Participants Edw...

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease PR Newswire BOSTON and ATLANTA , May 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a ...

2023-05-15 16:01:34 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q1 GAAP EPS of -$0.16 in-line. Revenue of $0.06M (+20.0% Y/Y). R&D Expenses: Research and development expenses were $2.9 million for the quarter ended March 31, 2023 compared to $3.0 mill...

2023-05-15 12:00:54 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q1 GAAP EPS of -$0.16 misses by $0.01 . Revenue of $0.6M (+1100.0% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.16 misses by $0.01, revenue of $0.6M

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call on Tuesday, May 16, 2023 at 8:00 a.m. ET BOSTON and ATLANTA , May 15, 2023 /PRNewswire/ -- Inhibi...

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 PR Newswire BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company dev...